The World Biotech Market 2005~
Published by Visiongain, June 2005
The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.~ Published by Visiongain, June 2005
The biopharmaceutical market has undergone rapid expansion since its emergence thirty years ago. No longer is the market confined to growth hormones, insulin and red blood cell stimulating agents. Innovative science driven by the 2001 human genome project is accelerating the market into targeting a huge range of diseases from growth deficiency to arthritis to multiple sclerosis and orphan diseases such as Fabry's disease.
Visiongain values the 2005 biopharma market at $70.8bn. Having grown 16.5% from 2004's revenues of $60.7bn, double-digit growth of the market will continue to the end of the decade. Composed of 9 major therapeutic areas including oncology, anti-infectives, vaccines and the market leader blood disorders, the market by 2010 is expected to represent 17% of all prescriptions written compared with 2004's 12%. At this pace of growth, biotech is now outgrowing Big Pharma.
At present the US dominates the biotech market and will do so for the rest of the forecast period. Japan and the EU will see a fall in global market share, whilst the Asia-Pacific region will see high levels of unprecedented growth.
Biotech companies however still face major challenges. The threat of the emergence of biogenerics is mounting, with 11 products facing patent expiry before 2007- 5 of which are blockbusters. The Australian approval of his Sandoz's Omnitrope hGH product is paving the way, and increasing pressure upon EU and US regulatory agencies to give the go ahead to biogenerics.
Designed as an essential business aid, World Biotech, 2005 provides a thorough and evaluation of the market that is of excellent value. This extensive report has the following chapter headings:
1. Executive Summary of the World Biotech Market
2. An Introduction to Biopharmaceuticals
3. Diseases treated by Biopharmaceuticals
4. Overview of Biopharmaceuticals Market, 2003-2004
5. Company Revenues and Market Share, 2004
6. Biopharmaceutical Pipeline, 2005
7. Biopharmaceutical Market Forecast by Therapeutic Area, 2003-2010
8. Summary of 2010 Biopharmaceuticals Market
9. Introduction to Biogenerics
10. The Potential Biogeneric Market
11. Biopharmaceutical Market Challenges
12. Venture Capitalism and Biotech
13: The Global Biopharmaceutical Market by Region, 2003-2010
14: The Human Genome Project and Its Influence on the Biotech Industry
15: Conclusion: Big Pharma Must Invest into the Biotech Arena
The report provides in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena
Why You Must Buy This Report?
This 262 paged report spanning 15 chapters features over 80 tables, 85 graphs and charts, news, insights and the latest developments. Over 120 companies are mentioned in this up-to-date report, which reviews 2004 revenues for all the biopharmaceutical products featured within the market.
Table of ContentsReport Overview ~The World Biotech Market 2005%3ASingle User license|206|The World Biotech Market 2005%3A Comnpany Wide license|699|~1409~976~~
Therapeutic Proteins~
Published by Visiongain, February 2005
Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.
In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues.~
Published by Visiongain, February 2005
Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.
In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues
Today therapeutic proteins are used to relieve patients suffering from many conditions, including:
Various cancers (Monoclonal antibodies, Interferons)
Heart attacks, strokes, cystic fibrosis, Gaucher's disease (Enzymes, Blood factors)
Diabetes (Insulin)
Anaemia (Erythropoietin)
Haemophilia (Blood clotting factors)
The leading therapeutic protein treatments in 2003 were:
Johnson & Johnson's anaemia treatment Procrit
Amgen's anaemia treatment Epogen
Schering-Plough's hepatitis treatments Intron A and Peg-Intron
The leading classes of therapeutic proteins in 2003 were:
Erythropoietins
Monoclonal antibodies
Interferons
While the top companies on the market were:
Amgen
Johnson & Johnson
Roche
WHY YOU MUST BUY THIS REPORT?
With over 80 graphs and figures, plus almost 60 tables, this report represents a key tool for companies wishing to enter into or expand in the therapeutic protein market. The reader will be left with a clear idea of:
The challenges faced by the therapeutic protein market, and how these are being overcome
The current and future market leaders in terms of brand, class, category and company, covering the period 2003-2010
Therapeutic targets currently being developed in the field and who is responsible for this developmen
The competition that companies will face during the forecast period from current and pipeline products
Sample Page~Therapeutic Proteins%3A Single User license|208|Therapeutic Proteins%3A Comnpany Wide license|588|~1409~1143~~